[1]JournalofMedicinalChemistry,2001,vol.44,p.4050-4061
[2]Patent:CN106083854,2016,A.Locationinpatent:Paragraph0056-0061;0081-0086;0106-0111;0131-0136;0156
Title: Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Journal: British journal of cancer 20110906
Title: Towards more specific O6-methylguanine-DNA methyltransferase (MGMT) inactivators.
Journal: Bioorganic & medicinal chemistry 20110301
Title: A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Journal: Cancer chemotherapy and pharmacology 20101001
Title: Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100115
Title: A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Journal: British journal of cancer 20090421
Title: O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Journal: British journal of cancer 20090421
Title: A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Journal: British journal of cancer 20080520
Title: MGMT inhibitors--The Trinity College-Paterson Institute experience, a chemist's perception.
Journal: DNA repair 20070801
Title: Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Journal: DNA repair 20070801
Title: Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070620
Title: O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
Journal: Pharmacological research 20060401
Title: The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Journal: The journal of gene medicine 20060101
Title: O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Journal: British journal of cancer 20051114
Title: Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells.
Journal: Carcinogenesis 20050801
Title: Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Journal: Molecular cancer therapeutics 20041001
Title: Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Journal: International journal of cancer 20020810
Title: Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships.
Journal: Journal of medicinal chemistry 20011122
Title: Reinhard J, et al. Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships. J Med Chem. 2001 Nov 22;44(24):4050-61.
Title: Clemons M, et al. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer. 2005 Nov 14;93(10):1152-6.